CD8A and Alzheimer disease: In comorbid AD/AA characterized by Th2 skewing, dupilumab inhibits Th2 responses, effectively counteracting Th2-driven IgE elevation and barrier damage in AD, while also suppressing Th2 cell-mediated assistance to pathogenic CD8+ T cells in AA.